Purpose. To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer. Patients and methods. In a phase II IRB approved trial, capecitabine was ...Purpose. To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer. Patients and methods. In a phase II IRB approved trial, capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7- day rest period. A standard dose modification scheme was used with one allowed dose reduction or dose escalation. National Cancer Institute criteria for progression, response, and toxicity were utilized. Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy, which included a subscale for cervical cancer. Results. Twenty of 23 enrolled patients were evaluable for response. Stable disease was noted in 5 patients, with a median duration of response of 3.5 months (range, 3- 6.5 months). No partial or complete responses were seen. Common grade 3 toxicities were fatigue (30.4% ); abdominal pain, constipation, hand-foot syndrome, nausea, and vomiting (8.7% each); as well as dyspnea, headache, and coagulopathy (4.3% each). There were no grade 4 toxicities. All patients with previous exposure to infused 5- FU had evidence of progression. No statistically significant changes in quality of life were noted from baseline to post-cycle 2. Conclusion. Single-agent capecitabine in patients with recurrent cervical cancer resulted in no objective responses. Although capecitabine is a welltolerated regimen, as a single agent, it offers minimal benefit in a poor-prognosis cervical cancer population.展开更多
Pro Cyte Corp.(Kitkland,WA)正在欧洲扩展其抗秃头药物Triccomin^TM的二期临床试验。迄今为此的前临床及临床试验均表明这种肽-铜药物可增加男性脱发症患者的毛发数量。目前,获准进入美国市场的治脱发药物只有Rogaine^Tm一种。Tricomi...Pro Cyte Corp.(Kitkland,WA)正在欧洲扩展其抗秃头药物Triccomin^TM的二期临床试验。迄今为此的前临床及临床试验均表明这种肽-铜药物可增加男性脱发症患者的毛发数量。目前,获准进入美国市场的治脱发药物只有Rogaine^Tm一种。Tricomin将是第二种。不过,道路还长得很。ProCyte还必须在美国进行前临床试验,更不用提还有三期临床试验等在前面。在欧洲进行的第二期临床试验将在第一季度结束。据公司称,接受涂抹治疗的24名患者中,80%出现良好的毛发生长状况。展开更多
文摘Purpose. To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer. Patients and methods. In a phase II IRB approved trial, capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7- day rest period. A standard dose modification scheme was used with one allowed dose reduction or dose escalation. National Cancer Institute criteria for progression, response, and toxicity were utilized. Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy, which included a subscale for cervical cancer. Results. Twenty of 23 enrolled patients were evaluable for response. Stable disease was noted in 5 patients, with a median duration of response of 3.5 months (range, 3- 6.5 months). No partial or complete responses were seen. Common grade 3 toxicities were fatigue (30.4% ); abdominal pain, constipation, hand-foot syndrome, nausea, and vomiting (8.7% each); as well as dyspnea, headache, and coagulopathy (4.3% each). There were no grade 4 toxicities. All patients with previous exposure to infused 5- FU had evidence of progression. No statistically significant changes in quality of life were noted from baseline to post-cycle 2. Conclusion. Single-agent capecitabine in patients with recurrent cervical cancer resulted in no objective responses. Although capecitabine is a welltolerated regimen, as a single agent, it offers minimal benefit in a poor-prognosis cervical cancer population.
